References
- United States Congress Office of Technology Assessment. New Developments in Biotechnology. U.S. Investment in Biotechnology. Special Report OTA-BA-360, U.S. Government Printing Office, Washington, DC July, 1988
- Reissman K. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood 1950; 5: 372–380
- U.S. Department of Health and Human Services Health Care Financing Administration. End Stage Renal Disease Program Quarterly Statistical Summary. Baltimore, MD November 9, 1989
- U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration. Summary Basis of Approval for Epoetin-alfa. Rockville, MD June, 1989
- Brenner B, Lazarus M. Chronic renal failure: pathophysiology and clinical considerations. Harrison's Principles of Internal Medicine, 11th Ed., R Petersdorf, et al. McGraw Hill, New York 1987
- Eschbach J, Abdulhadi M, Browne J, et al. Recombinant human erythropoietin in anemic patients with end stage renal disease: results of a Phase HI multicenter clinical trial. Ann Int Med 1989
- Amgen, Inc. The Economic Impact of Epogen (Epoetin-alfa). Recombinant Human Erythropoietin Therapy. June, 1989, unpublished manuscript
- Eggers P. Effect of transplantation on the Medicare end-stage renal disease program. N Engl J Med 1988; 318(4)223–229
- Ortho Pharmaceutical Corporation, Biotechnology Division. Eprex: Treatment Program for Anemia in AIDS Patients. Raritan, NJ May, 1989
- Will Biotechnology Finally Deliver?. New York Times 1989, Sunday, September 3
- Burrill S. Biotechnology product pricing: issues, concerns strategies. Biopharm June, 1989
- U.S. Department of Health and Human Services. Health Care Financing Administration. Medicare Carriers Manual, Part 3-Claims Processing. Transmittal 1449, November, 1989
- U.S. Department of Health and Human Services. Health Care Financing Administration, Medicare Provider Relations Manual. Reimbursement for ESRD Services and Supplies. Baltimore, MD July, 1989, Part 1, Chap 27, Transmittal 6